Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018
Download the sample report @ www.pharmaproff.com/request-sample/1126
The interstitium is a lace like network of the tissue that provide support to the air sacs and the capillaries in the interstitium which allows the gas exchange between the blood and alveolar tissues.
Get the detailed analysis @ www.pharmaproff.com/report/interstitial-lung-disease-ther...
Some of the types of the condition include interstitial pneumonia, idiopathic pulmonary fibrosis, and non-specific interstitial pneumonitis. Major symptoms associated with the disease include dry cough and shortness of breath.
Make enquiry before purchase @ www.pharmaproff.com/enquiry/1126
Regend Therapeutics is in the process of developing lung stem cells as a cell therapy for the treatment of interstitial lung disease. Boehringer Ingelheim GmbH is in the process of developing nintedanib as a fibroblast growth factor receptor antagonist for the treatment of this medical condition.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Toll-free: +1-888-778-7886 (USA/Canada)
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Interstitial Lung Disease Therapeutics - Pipeline Analysis 2018 here
News-ID: 1721711 • Views: 159